| خلاصه مقاله | Background: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. This study aimed to examine the crucial miRNAs, transcription factors, and circRNAs associated with hub-genes involved in AML survival.
Method: The TCGA LAML dataset from GEPIA2 was used to identify all DEGs linked with LAML among high throughput RNA-Seq data. A protein-protein interaction (PPI) network of significant genes was constructed with STRING at the Cytoscape. The hub-genes with more degrees were chosen, and we used Pan-cancer analysis with GEPIA2 and UALCAN for hub-genes and found NDUFS8. hTFtarget was used for transcription factors associated with NDUFS8, which are involved in blood and bone marrow. Also, mirtarbase, target scan, mirDB, and mirwalk were used to find miRNA and ultimately identify circRNAs that regulate NDUFS8, so circBank database26 was utilized. Using Cytoscape,27, a ceRNA network was established, encompassing selected genes, their TFs, miRNAs, and circRNAs. Also, hub-nodes of the ceRNAs network were identified.
Result: Out of 7965genes acquired from TCGA-RNAseq, 843genes are considered significant, and eight genes were considered hub-genes, which, with pan-cancer analysis, NDUFS8 is one of the 4genes that are expressed significantly less than usual (Compared with other cancers as well as with normal samples). We found 93TF associated with blood and bone marrow, 25miRNAs from 3databases (16 target scan,8mirWalk,1mirTarbase,0mirDB) and 7cirRNAs (including hsa_circ_0023138,hsa_circ_0023139,hsa_circ_0096261,hsa_circ_0023140,hsa_circ_0023141,hsa_circ_0023142,hsa_circ_0023143). We also designed a ceRNA network and identified hub-nodes.
Conclusion: In summary, the present study demonstrates that NDUFS8 is a differentially expressed gene in AML, playing a strong down-prognostic role in overall survival. Also, by evaluating the diagnostic value of NDUFS8 and the CeRNA network, we conclude that NDUFS8 may serve as a reliable biomarker in diagnosing and treating responses and can be a promising gene to be targeted by AML drugs in the future. |